Shijiazhuang Yiling Pharmaceutical Co Ltd (002603) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shijiazhuang Yiling Pharmaceutical Co Ltd (002603) has a cash flow conversion efficiency ratio of 0.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥446.51 Million ≈ $65.34 Million USD) by net assets (CN¥10.70 Billion ≈ $1.57 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Shijiazhuang Yiling Pharmaceutical Co Lt defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Shijiazhuang Yiling Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Shijiazhuang Yiling Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Shijiazhuang Yiling Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shijiazhuang Yiling Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Airoha Technology Corp
TW:6526
|
0.071x |
|
Otter Tail Corporation
NASDAQ:OTTR
|
0.037x |
|
Beijing Shougang Co Ltd
SHE:000959
|
0.059x |
|
Cal-Maine Foods Inc
NASDAQ:CALM
|
0.038x |
|
OSI Systems Inc
NASDAQ:OSIS
|
0.074x |
|
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
|
0.027x |
|
Sime Darby Bhd
KLSE:4197
|
0.065x |
|
Huaxin Cement Co Ltd A
SHG:600801
|
0.092x |
Annual Cash Flow Conversion Efficiency for Shijiazhuang Yiling Pharmaceutical Co Ltd (2008–2025)
The table below shows the annual cash flow conversion efficiency of Shijiazhuang Yiling Pharmaceutical Co Ltd from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see Shijiazhuang Yiling Pharmaceutical Co Lt (002603) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥10.98 Billion ≈ $1.61 Billion |
CN¥1.78 Billion ≈ $259.96 Million |
0.162x | +170.10% |
| 2024-12-31 | CN¥10.20 Billion ≈ $1.49 Billion |
CN¥611.01 Million ≈ $89.41 Million |
0.060x | +340.66% |
| 2023-12-31 | CN¥11.44 Billion ≈ $1.67 Billion |
CN¥155.46 Million ≈ $22.75 Million |
0.014x | -95.74% |
| 2022-12-31 | CN¥10.93 Billion ≈ $1.60 Billion |
CN¥3.49 Billion ≈ $510.37 Million |
0.319x | +447.55% |
| 2021-12-31 | CN¥9.07 Billion ≈ $1.33 Billion |
CN¥528.69 Million ≈ $77.36 Million |
0.058x | -67.22% |
| 2020-12-31 | CN¥8.92 Billion ≈ $1.31 Billion |
CN¥1.59 Billion ≈ $232.11 Million |
0.178x | +1950.92% |
| 2019-12-31 | CN¥7.95 Billion ≈ $1.16 Billion |
CN¥68.93 Million ≈ $10.09 Million |
0.009x | -9.41% |
| 2018-12-31 | CN¥7.56 Billion ≈ $1.11 Billion |
CN¥72.37 Million ≈ $10.59 Million |
0.010x | -40.65% |
| 2017-12-31 | CN¥7.11 Billion ≈ $1.04 Billion |
CN¥114.65 Million ≈ $16.78 Million |
0.016x | -86.60% |
| 2016-12-31 | CN¥5.33 Billion ≈ $780.36 Million |
CN¥641.45 Million ≈ $93.86 Million |
0.120x | +340.29% |
| 2015-12-31 | CN¥4.83 Billion ≈ $706.40 Million |
CN¥131.88 Million ≈ $19.30 Million |
0.027x | +13.93% |
| 2014-12-31 | CN¥4.42 Billion ≈ $646.31 Million |
CN¥105.90 Million ≈ $15.50 Million |
0.024x | +84.57% |
| 2013-12-31 | CN¥4.26 Billion ≈ $623.13 Million |
CN¥55.32 Million ≈ $8.10 Million |
0.013x | -28.77% |
| 2012-12-31 | CN¥3.84 Billion ≈ $562.64 Million |
CN¥70.13 Million ≈ $10.26 Million |
0.018x | +116.53% |
| 2011-12-31 | CN¥3.70 Billion ≈ $541.67 Million |
CN¥-408.49 Million ≈ $-59.77 Million |
-0.110x | -140.17% |
| 2010-12-31 | CN¥1.09 Billion ≈ $159.65 Million |
CN¥299.72 Million ≈ $43.86 Million |
0.275x | -31.75% |
| 2009-12-31 | CN¥790.55 Million ≈ $115.68 Million |
CN¥318.21 Million ≈ $46.56 Million |
0.403x | -7.30% |
| 2008-12-31 | CN¥484.03 Million ≈ $70.83 Million |
CN¥210.18 Million ≈ $30.76 Million |
0.434x | -- |
About Shijiazhuang Yiling Pharmaceutical Co Ltd
Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicine in China and internationally. It offers dietary supplements, and healthy food and drinks; patent TCM products for respiratory health, cardiovascular disease, diabetes, mellitus, oncology, urologic disease, sleep-improving, and anti-aging; disinfection and pers… Read more